5 Best High Volume Penny Stocks to Buy Now

4. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

On March 12, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), in line with the (12c) consensus estimate. CEO Faraz Ali said the company is entering the year with “momentum” following clinical progress in 2025, highlighting encouraging data from its lead gene therapy programs. Ali noted that Tenaya expects to provide additional updates in the first half of 2026, including longer-term data from the MyPEAK-1 trial of TN-201 and new data from the RIDGE-1 trial of TN-401, while also working toward regulatory alignment on pivotal trial plans.

On March 9, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) presented preclinical data for TN-301, its selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026. In models of Duchenne muscular dystrophy, TN-301 improved muscle performance and addressed markers of muscle injury, including reductions in creatine kinase activity. The compound also showed improvements in cardiac-related cellular function, including correcting calcium handling abnormalities and mitochondrial dysfunction in human-derived cardiomyocytes.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) develops gene and small molecule therapies targeting heart disease, with programs focused on cardiomyopathies and heart failure.